Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:48:22.188Z.
Consensus retrieved: 2026-10-06T16:50:13.665Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:48:22.188Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 91899883c476d55b2433093e583c87952940339a9b77bc55d8a3dd78c9ec7759
Forward PE Ratio (N/A) = Dated Quote Price ($4.65) / Consensus Forward EPS ($-0.94)
FORWARD PE RATIO
N/A
Savara Inc.
Market Cap
$952.91M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Savara Inc. (SVRA) | $952.91M | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | N/A |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $929.83M | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 35.33 |
| CeriBell, Inc. (CBLL)vs › | $923.53M | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.65, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.94 | $-1.26 – $-0.62 | 5 | n/m |
| 2027-12-31 | $-0.36 | $-0.63 – $-0.09 | 5 | n/m |
| 2028-12-31 | $0.07 | $-0.19 – $0.71 | 6 | 62.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
